Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Welfare Offices to Dispatch “Advisors” to Visit Welfare Recipients and Encourage Generic Drug Use
February 27, 2012
- Health Insurance Law Revision Study Group Formed, Calling for Legal Presence for Regulatory Guidance
February 24, 2012
- Measures to Eliminate Drug Lag “Fully Implemented”: GRU Report
February 24, 2012
- Novartis Pharma’s Pasireotide Designated as Orphan Drug for Cushing’s Disease
February 24, 2012
- PAFSC Committee on New Drugs Approves Orphan Drug Designation for 3 Products
February 24, 2012
- DPJ’s PAL Subcommittee to Form Opinion on Amendment of PAL in March
February 23, 2012
- MEXT to Make Drug Education Compulsory at Junior High Schools from FY2012
February 23, 2012
- MHLW to Promote Multinational Clinical Trials in East Asia to Reduce Drug Lag
February 23, 2012
- MHLW Plans to Set Up Medical Information Database at 6 Base Locations in FY2012
February 22, 2012
- MHLW to Improve Review System Based on Regulatory Science: PFSB Director General Yoshiyuki Kikura
February 22, 2012
- MHLW Warns Manufacturers to Take Steps to Ensure Proper Use of Anti-Influenza Drugs
February 22, 2012
- MHLW Issues Notification to Publicize FPMAJ’s Crude and Kampo Drug Standards
February 20, 2012
- MHLW Issues Improvement Order to Janssen Pharmaceutical for GMP Violation
February 20, 2012
- Domestic Pharmaceutical Production Down 0.6% in 2010; First Decline in Six Years
February 20, 2012
- 105 Nu-lotan Generics from 35 Companies Approved for June Listing, 60% Pricing to Apply
February 16, 2012
- Medical Innovation Council Executive Meeting to Set Next 5-Year Plan by May
February 16, 2012
- MHLW to Revise Notification on GMP Inspection Requirements to Prepare for Participation in PIC/S
February 16, 2012
- PAFSC’s 2nd Committee on New Drugs to Discuss Approval for Pfizer Japan’s ALK Inhibitor Xalkori
February 16, 2012
- Osaka Prefecture Asking Korosho to Provide Pharmaceutical Strategy Consultation Services in Kansai Region
February 16, 2012
- Over 30 Companies Target Nu-lotan Generic Listing in June, 60% Pricing Rule to Apply
February 15, 2012
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…